The goal with this series was to remove unnecessary complexity and focus purely on the practice learners actually ...
First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician’s ...
A research team at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) has developed a radiopharmaceutical molecule marker that ...
The startup is developing a medicine that can very specifically degrade cancerous forms of EGFR, the target of several ...
Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) (Salarius) announces it will change its corporate name to Decoy Therapeutics Inc. (Decoy) and its common shares will trade on the Nasdaq Capital Market ...
Fibre and product converting company Teijin Frontier has developed a new “multi-functional comfort” textile intended for use ...
Harpreet S. Dhaliwal, Chief Technical Ops Officer of Vaxcyte(NASDAQ:PCVX), disposed of 9,743 shares in an open-market sale valued at approximately $454,891 according to the SEC Form 4 filing.
Daiichi Sankyo and GENESIS Pharma will distribute and commercialize quizartinib, brand name VANFLYTA, in 13 markets.
Create a Physics World account to get access to all available digital issues of the monthly magazine. Your Physics World account is sep ...
As we head into the 2026, let's take a look at biotech licensing deals and M&As that were inked in December 2025.
Name change to Kyntra Bio reflects the newly sharpened focus of the Company on novel therapies with potential for outsized impact in oncology and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback